BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22330890)

  • 1. Current status and future challenges of CAR-T cell therapy for osteosarcoma.
    Li S; Zhang H; Shang G
    Front Immunol; 2023; 14():1290762. PubMed ID: 38187386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
    Lipowska-Bhalla G; Gilham DE; Hawkins RE; Rothwell DG
    Cancer Immunol Immunother; 2012 Jul; 61(7):953-62. PubMed ID: 22527245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor.
    Krug C; Wiesinger M; Abken H; Schuler-Thurner B; Schuler G; Dörrie J; Schaft N
    Cancer Immunol Immunother; 2014 Oct; 63(10):999-1008. PubMed ID: 24938475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
    Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
    Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen processing and presentation-related signature-derived BNIP3 is a novel oncogene and immunotherapy determinant in osteosarcoma based on machine learning and in vitro validation.
    Chen Y; Cao Y; Wu S; Cao X; Cai T; Hu H
    J Gene Med; 2024 Jan; 26(1):e3586. PubMed ID: 37655535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
    Merchant MS; Melchionda F; Sinha M; Khanna C; Helman L; Mackall CL
    Cancer Immunol Immunother; 2007 Jul; 56(7):1037-46. PubMed ID: 17149595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for Pediatric Gliomas: CAR-T Cells Against B7H3: A Review of the Literature.
    Santiago-Vicente Y; de Jesús Castillejos-López M; Carmona-Aparicio L; Coballase-Urrutia E; Velasco-Hidalgo L; Niembro-Zúñiga AM; Zapata-Tarrés M; Torres-Espíndola LM
    CNS Neurol Disord Drug Targets; 2024; 23(4):420-430. PubMed ID: 37038673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall review of curative impact and barriers of CAR-T cells in osteosarcoma.
    Li G; Wang H; Meftahpour V
    EXCLI J; 2024; 23():364-383. PubMed ID: 38655095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell responses to tumor: how dominant assumptions on immune activity led to a neglect of pathological functions, and how evolutionary considerations can help identify testable hypotheses for improving immunotherapy.
    Kallikourdis M
    Cancer Immunol Immunother; 2018 Jun; 67(6):989-998. PubMed ID: 29335855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
    Makuku R; Khalili N; Razi S; Keshavarz-Fathi M; Rezaei N
    J Immunol Res; 2021; 2021():6661406. PubMed ID: 33681388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generating Recombinant Antibodies to Membrane Proteins through Phage Display.
    Huang R; Kiss MM; Batonick M; Weiner MP; Kay BK
    Antibodies (Basel); 2016 May; 5(2):. PubMed ID: 31557992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
    Shirasu N; Kuroki M
    Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
    Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
    Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
    Miliotou AN; Papadopoulou LC
    Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen.
    Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M
    Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
    Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
    Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
    [No Abstract]   [Full Text] [Related]  

  • 17. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
    Weibo P; Zhaoming Y
    Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.